Generic name: revefenacin 175ug in 3mL
Dosage form: inhalation solution
Medically reviewed by Drugs.com. Last updated on May 29, 2019.
The recommended dose of YUPELRI inhalation solution is one 175 mcg unit‑dose vial administered once daily by nebulizer using a mouthpiece.
YUPELRI should be administered by the orally inhaled route via a standard jet nebulizer connected to an air compressor (See Patient Information). The safety and efficacy of YUPELRI have been established in clinical trials when administered using the PARI LC® Sprint nebulizer with a mouthpiece and the PARI Trek® S compressor. The safety and efficacy of YUPELRI delivered from non‑compressor based nebulizer systems have not been established.
The YUPELRI unit-dose vial should only be removed from the foil pouch and opened IMMEDIATELY BEFORE USE. The vial and any residual content should be discarded after use.
The drug compatibility (physical and chemical), efficacy, and safety of YUPELRI when mixed with other drugs in a nebulizer have not been established.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Frequently Asked Questions
More about Yupelri (revefenacin)
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Drug class: anticholinergic bronchodilators
- FDA Approval History